Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study to Assess the Efficacy and Safety of CAL-101 in Patients With Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents

Next Previous
Trial Profile

A Phase 2 Study to Assess the Efficacy and Safety of CAL-101 in Patients With Indolent B-Cell Non-Hodgkin Lymphoma Refractory to Rituximab and Alkylating Agents

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Idelalisib (Primary)
  • Indications Chronic lymphocytic leukaemia; Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Therapeutic Use
  • Acronyms DELTA
  • Sponsors Gilead Sciences

    • Most Recent Events

    • 01 May 2021 Results assessing final efficacy and safety data published in the Leukemia and Lymphoma
    • 01 Apr 2021 Results of a post hoc analysis of data pooled from 2 trials (NCT01539512 and NCT01282424) assessing the degree of comorbidity burden and the impact of Idelalisib on bleeding events published in the Leukemia and Lymphoma
    • 21 Jun 2020 Results (N=408), pooled analysis of 4 studies assessing efficacy of Idelalisib in patients with indolent non Hodgkins lymphoma and CLL, presented at the 25th Congress of the European Haematology Association
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top